Published 7 days ago • loading... • Updated 7 days ago
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Preliminary Phase 1 data showed signs of Treg activation and improvement in some alopecia areata patients, while no dose-limiting toxicities were reported.